InfuSystem Holdings, Inc. provides health care services that facilitate outpatient care for durable medical equipment manufacturers and health care providers. News for INFU commonly covers financial results, segment trends and operating updates across Patient Services and Device Solutions, including oncology, pain management, wound therapy, direct payer rentals, pump and consumable sales, and biomedical services and repair.
Company updates also address revenue cycle management, payer-network and billing efficiency initiatives, relationships with DME manufacturers, contract economics, margin performance, cash flow, guidance and management presentations at investor conferences.
InfuSystem (INFU) postponed its third-quarter 2026 financial results release, previously scheduled for November 3, to complete its quarter-end financial reporting process. The results cover the quarter ended September 30, 2026. The company expects to announce a revised release and conference call date as soon as practicable.
InfuSystem, its Audit Committee and its independent accounting firm are evaluating whether implementation costs for its new enterprise resource planning (ERP) system should be capitalized and amortized—recorded as an asset and spread over the software subscription agreement’s remaining three-year term—rather than expensed as incurred. The system went live March 1, 2026. Costs totaling $4.2 million were expensed from July 1, 2024 to March 1, 2026. Any adjustment would be non-cash and would not affect revenue or cash balances.
InfuSystem Holdings (INFU) will release its third quarter 2026 financial results on November 3, 2026, before the market opens.
The company will hold a conference call that day at 9:00 a.m. Eastern Time to discuss the results. A live webcast and replay will be available through its investor website.
InfuSystem (INFU) will host an investor webcast presentation on September 24, 2026 at 2:00 p.m. Eastern Time.
President and CEO Carrie Lachance and EVP/CFO Barry Steele will give an introductory presentation on the company’s business, including corporate strategy, business model, and growth initiatives, followed by an interactive investor Q&A. Participants can register via the provided Zoom link, and the webcast link will also be accessible through InfuSystem’s investor relations website.
InfuSystem (NYSE American: INFU) reported second quarter 2026 net revenues of $36.9 million, up 2.6% year over year. Patient Services revenue rose 15.2% to $24.8 million, while Device Solutions revenue fell 16.1% to $12.1 million, reflecting a restructured GE Healthcare biomedical services contract and lower equipment sales.
Gross profit increased 7.7% to $21.4 million with gross margin improving to 58.0%. Net income was $3.2 million, or $0.15 per diluted share, versus $2.6 million, or $0.12, a year ago. Adjusted EBITDA (non-GAAP) grew 7.6% to $8.6 million, with margin expanding to 23.4%. Operating cash flow for the first half was $7.7 million, down 12% on higher working capital.
The company invested $6.5 million in medical devices in the first half and repurchased $4.4 million of stock, including $3.5 million in Q2. Liquidity totaled $55.2 million at June 30, 2026, with net debt of $19.5 million. InfuSystem reaffirmed full-year 2026 guidance for 6%–8% pro forma revenue growth and mid- to low-20% Adjusted EBITDA margins (non-GAAP).
InfuSystem (NYSE American: INFU) will release its second quarter 2026 financial results on Tuesday, August 4, 2026, before the market opens. The company will host an investor conference call the same day at 9:00 a.m. Eastern Time to discuss the results, with live webcast and telephone access plus a replay available via its investor relations website.
InfuSystem (NYSE American: INFU) announced Board approval of a new $20 million stock repurchase program. The authorization covers buybacks of common stock from July 1, 2026 through June 30, 2028 and will supersede the current plan expiring June 30, 2026.
Under the existing authorization, InfuSystem repurchased about 1.6 million shares for $11.9 million through March 31, 2026. According to the company, buybacks complement its priority of funding strategic investments to support sustainable growth while providing flexibility to repurchase shares when valuations are considered attractive.
InfuSystem (NYSE:INFU) reported Q1 2026 results: net revenue $33.7M (down 3% YoY), net income $1.0M, and Adjusted EBITDA $6.4M with an 18.9% margin. Patient Services revenue rose to $22.1M (+6%); Device Solutions fell to $11.6M (-17%). Company reaffirmed full‑year 2026 guidance and noted available liquidity of $57.1M.
InfuSystem (NYSE American: INFU) will report its first quarter 2026 financial results on Thursday, May 7, 2026, before market open, and will host an investor conference call at 9:00 a.m. Eastern Time.
Dial-in numbers, live webcast access, and replay details are available on the company's investor website; replay access runs through May 14, 2026.
InfuSystem (NYSE American: INFU) announced that CEO Carrie Lachance and CFO Barry Steele will participate in the 38th Annual ROTH Conference on March 23, 2026 at The Ritz-Carlton Laguna Niguel in Dana Point, California.
Management will hold in-person one-on-one meetings; investors may request meetings through their ROTH Capital representative or the conference registration portal.
InfuSystem (NYSE:INFU) reported fourth quarter and full year 2025 results, with record net revenues of $143.4M (up 6%) and net income of $6.6M (up 183%). Adjusted EBITDA reached $31.5M (up 24%) and operating cash flow was $24.4M (up 19%).
The company reduced net debt 30%, held $58.2M liquidity, repurchased 1.3M shares in 2025 and expects 2026 pro-forma revenue growth of 6%–8% with Adjusted EBITDA margins in the mid-to-low 20% range, after a $7.1M annual revenue reduction from a restructured biomedical services contract.